Journal of International Oncology››2022,Vol. 49››Issue (1): 12-25.doi:10.3760/cma.j.cn371439-20211021-00002
Previous ArticlesNext Articles
Received:2021-10-21Revised:2021-12-05Online:2022-01-08Published:2022-01-17. [J]. Journal of International Oncology, 2022, 49(1): 12-25.
"
"
| [1] | NCCN Guidelines of Esophageal and Esophagogastric Junction Cancers, Version 2. 2021[EB/OL]. [2021-06-22]. https://www.nccn.org/. |
| [2] | He Y, Li D, Shan B, et al. Incidence and mortality of esophagus cancer in China, 2008-2012[J]. Chin J Cancer Res, 2019, 31(3):426-434. DOI: 10.21147/j.issn.1000-9604.2019.03.04. doi:10.21147/j.issn.1000-9604.2019.03.04 |
| [3] | 中国抗癌协会食管癌专业委员会. 食管癌规范化诊治指南[M]. 北京: 中国协和医科大学出版社, 2011. |
| [4] | Gibault L, Metges JP, Conan-Charlet V, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oeso-phageal squamous cell cancer[J]. Br J Cancer, 2005, 93(1):107-115. DOI: 10.1038/sj.bjc.6602625. doi:10.1038/sj.bjc.6602625 |
| [5] | Tsutsumi S, Saeki H, Nakashima Y, et al. Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma[J]. Cancer Sci, 2017, 108(6):1119-1127. DOI: 10.1111/cas.13237. doi:10.1111/cas.13237 |
| [6] | Bunting D, Bracey T, Fox B, et al. Loco-regional staging accuracy in esophageal cancer-How good are we in the modern era?[J]. Eur J Radiol, 2017, 97(1):71-75. DOI: 10.1016/j.ejrad.2017.10.015. doi:10.1016/j.ejrad.2017.10.015 |
| [7] | el-Khoury GY, Dalinka MK, Alazraki N, et al. Metastatic bone disease. American College of Radiology. ACR Appropriateness Criteria[J]. Radiology, 2000, 215 Suppl: 283-293. |
| [8] | Minashi K, Nihei K, Mizusawa J, et al. Efficacy of endoscopic resection and selective chemoradiotherapy for stage Ⅰ esophageal squamous cell carcinoma[J]. Gastroenterology, 2019, 157(2): 382-390. e3. DOI: 10.1053/j.gastro.2019.04.017. doi:S0016-5085(19)36710-1pmid:31014996 |
| [9] | Kato H, Sato A, Fukuda H, et al. A phase Ⅱ trial of chemoradiotherapy for stage Ⅰ esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708)[J]. Jpn J Clin Oncol, 2009, 39(10):638-643. DOI: 10.1093/jjco/hyp069. doi:10.1093/jjco/hyp069 |
| [10] | Juloori A, Tucker SL, Komaki R, et al. Influence of preoperative radiation field on postoperative leak rates in esophageal cancer patients after trimodality therapy[J]. J Thorac Oncol, 2014, 9(4):534-540. DOI: 10.1097/JTO.0000000000000100. doi:10.1097/JTO.0000000000000100pmid:24736077 |
| [11] | Huang W, Huang Y, Sun J, et al. Atlas of the thoracic lymph nodal delineation and recommendations for lymph nodal CTV of esophageal squamous cell cancer in radiation therapy from China[J]. Radiother Oncol, 2015, 116(1):100-106. DOI: 10.1016/j.radonc.2015.06.024. doi:10.1016/j.radonc.2015.06.024pmid:26142269 |
| [12] | Huang W, Li B, Gong H, et al. Pattern of lymph node metastases and its implication in radiotherapeutic clinical target volume in patients with thoracic esophageal squamous cell carcinoma: a report of 1077 cases[J]. Radiother Oncol, 2010, 95(2):229-233. DOI: 10.1016/j.radonc.2010.01.006. doi:10.1016/j.radonc.2010.01.006pmid:20189259 |
| [13] | Cheng J, Kong L, Huang W, et al. Explore the radiotherapeutic clinical target volume delineation for thoracic esophageal squamous cell carcinoma from the pattern of lymphatic metastases[J]. J Thorac Oncol, 2013, 8(3):359-365. DOI: 10.1097/JTO.0b013e-31827e1f6d. doi:10.1097/JTO.0b013e31827e1f6dpmid:23263689 |
| [14] | Ding X, Zhang J, Li B, et al. A meta-analysis of lymph node metastasis rate for patients with thoracic oesophageal cancer and its implication in delineation of clinical target volume for radiation therapy[J]. Br J Radiol, 2012, 85(1019):e1110-e1119. DOI: 10.1259/bjr/12500248. doi:10.1259/bjr/12500248pmid:22700258 |
| [15] | Dong Y, Guan H, Huang W, et al. Precise delineation of clinical target volume for crossing-segments thoracic esophageal squamous cell carcinoma based on the pattern of lymph node metastases[J]. J Thorac Dis, 2015, 7(12):2313-2320. DOI: 10.3978/j.issn.2072-1439.2015.12.10. doi:10.3978/j.issn.2072-1439.2015.12.10 |
| [16] | Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015, 16(9):1090-1098. DOI: 10.1016/S1470-2045(15)00040-6. doi:S1470-2045(15)00040-6pmid:26254683 |
| [17] | van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22):2074-2084. DOI: 10.1056/NEJMoa1112088. doi:10.1056/NEJMoa1112088 |
| [18] | 王玉祥, 杨琼, 何明, 等. Ⅲ期胸段食管鳞癌根治术后的复发规律[J]. 中华肿瘤杂志, 2017, 39(1):48-55. DOI: 10.3760/cma.j.issn.0253-3766.2017.01.010. doi:10.3760/cma.j.issn.0253-3766.2017.01.010 |
| [19] | Chapet O, Kong FM, Quint LE, et al. CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan[J]. Int J Radiat Oncol Biol Phys, 2005. 63(1):170-178. DOI: 10.1016/j.ijrobp.2004.12.060. doi:10.1016/j.ijrobp.2004.12.060 |
| [20] | Liu Q, Cai XW, Wu B, et al. Patterns of failure after radical sur-gery among patients with thoracic esophageal squamous cell carcinoma: implications for the clinical target volume design of postoperative radiotherapy[J]. PLoS One, 2014, 9(5):e97225. DOI: 10.1371/journal.pone.0097225. doi:10.1371/journal.pone.0097225 |
| [21] | Wong AT, Shao M, Rineer J, et al. The impact of adjuvant post-operative radiation therapy and chemotherapy on survival after esophagectomy for esophageal carcinoma[J]. Ann Surg, 2017, 265(6):1146-1151. DOI: 10.1097/SLA.0000000000001825. doi:10.1097/SLA.0000000000001825 |
| [22] | Xiao ZF, Yang ZY, Liang J, et al. Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients[J]. Ann Thorac Surg, 2003, 75(2):331-336. DOI: 10.1016/s0003-4975(02)04401-6. doi:10.1016/s0003-4975(02)04401-6pmid:12607634 |
| [23] | Worni M, Martin J, Gloor B, et al. Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008[J]. J Am Coll Surg, 2012, 215(5):643-651. DOI: 10.1016/j.jamcollsurg.2012.07.006. doi:10.1016/j.jamcollsurg.2012.07.006 |
| [24] | Chen J, Zhu J, Pan J, et al. Postoperative radiotherapy improved survival of poor prognostic squamous cell carcinoma esophagus[J]. Ann Thorac Surg, 2010, 90(2):435-442. DOI: 10.1016/j.athoracsur.2010.04.002. doi:10.1016/j.athoracsur.2010.04.002 |
| [25] | Schreiber D, Rineer J, Vongtama D, et al. Impact of postoperative radiation after esophagectomy for esophageal cancer[J]. J Thorac Oncol, 2010, 5(2):244-250. DOI: 10.1097/JTO.0b013e-3181c5e34f. doi:10.1097/JTO.0b013e3181c5e34fpmid:20009774 |
| [26] | Shridhar R, Weber J, Hoffe SE, et al. Adjuvant radiation therapy and lymphadenectomy in esophageal cancer: a SEER database analysis[J]. J Gastrointest Surg, 2013, 17(8):1339-1345. DOI: 10.1007/s11605-013-2192-7. doi:10.1007/s11605-013-2192-7pmid:23749498 |
| [27] | Xu Y, Liu J, Du X, et al. Prognostic impact of postoperative radiation in patients undergoing radical esophagectomy for pathologic lymph node positive esophageal cancer[J]. Radiat Oncol, 2013, 8:116. DOI: 10.1186/1748-717X-8-116. doi:10.1186/1748-717X-8-116 |
| [28] | Zhang W, Liu X, Xiao Z, et al. Postoperative intensity-modulated radiotherapy improved survival in lymph node-positive or stage Ⅲ thoracic esophageal squamous cell carcinoma[J]. Oncol Res Treat, 2015, 38(3):97-102. DOI: 10.1159/000375391. doi:10.1159/000375391 |
| [29] | Chen SB, Weng HR, Wang G, et al. The impact of adjuvant radiotherapy on radically resected T3esophageal squamous cell carcinoma[J]. J Cancer Res Clin Oncol, 2016, 142(1):277-286. DOI: 10.1007/s00432-015-2041-z. doi:10.1007/s00432-015-2041-z |
| [30] | 刘晓, 章文成, 于舒飞, 等. T2-3N0M0期食管癌R0术后失败模式分析——术后放疗潜在价值与意义[J]. 中华放射肿瘤学杂志, 2015, 24(1):19-24. DOI: 10.3760/cma.j.issn.1004-4221.2015.01.006. doi:10.3760/cma.j.issn.1004-4221.2015.01.006 |
| [31] | Yang J, Zhang W, Xiao Z, et al. The impact of postoperative conformal radiotherapy after radical surgery on survival and recurrence in pathologic T3N0M0esophageal carcinoma: a propensity score-matched analysis[J]. J Thorac Oncol, 2017, 12(7):1143-1151. DOI: 10.1016/j.jtho.2017.03.024. doi:10.1016/j.jtho.2017.03.024 |
| [32] | 徐裕金, 朱卫国, Liao ZX, 等. 同步放化疗60 Gy对比50 Gy剂量治疗不可手术食管鳞状细胞癌的多中心随机对照研究[J]. 中华医学杂志, 2020, 100(23):1-6. DOI: 10.3760/cma.j.cn112137-20200303-00574. doi:10.3760/cma.j.cn112137-20200303-00574 |
| [33] | Ji Y, Du X, Zhu W, et al. Efficacy of concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: a multicenter randomized phase 3 clinical trial[J]. JAMA Oncol, 2021, 7(10):1459-1466. DOI: 10.1001/jamaoncol.2021.2705. doi:10.1001/jamaoncol.2021.2705 |
| [34] | Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl):S42-S49. DOI: 10.1016/j.ijrobp.2009.04.095. doi:10.1016/j.ijrobp.2009.04.095 |
| [35] | Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl):S10-S19. DOI: 10.1016/j.ijrobp.2009.07.1754. doi:10.1016/j.ijrobp.2009.07.1754 |
| [36] | Mizumoto M, Sugahara S, Nakayama H, et al. Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer[J]. Strahlenther Onkol, 2010, 186(9):482-488. DOI: 10.1007/s00066-010-2079-4. doi:10.1007/s00066-010-2079-4pmid:20803187 |
| [37] | Xi M, Xu C, Liao Z, et al. Comparative outcomes after definitive chemoradiotherapy using proton beam therapy versus intensity modulated radiation therapy for esophageal cancer: a retrospective, single-institutional analysis[J]. Int J Radiat Oncol Biol Phys, 2017, 99(3):667-676. DOI: 10.1016/j.ijrobp.2017.06.2450. doi:10.1016/j.ijrobp.2017.06.2450 |
| [38] | Fernandes A, Berman AT, Mick RA, et al. Prospective study of proton beam reirradiation for esophageal cancer[J]. Int J Radiat Oncol Biol Phys, 2016, 95(1):483-487. DOI: 10.1016/j.ijrobp.2015.12.005. doi:10.1016/j.ijrobp.2015.12.005 |
| [39] | Routman DM, Garant A, Lester SC, et al. A comparison of grade 4 lymphopenia with proton versus photon radiation therapy for esophageal cancer[J]. Adv Radiat Oncol, 2019, 4(1):63-69. DOI: 10.1016/j.adro.2018.09.004. doi:10.1016/j.adro.2018.09.004pmid:30706012 |
| [40] | Akutsu Y, Yasuda S, Nagata M, et al. A phase Ⅰ/Ⅱ clinical trial of preoperative short-course carbon-ion radiotherapy for patients with squamous cell carcinoma of the esophagus[J]. J Surg Oncol, 2012, 105(8):750-755. DOI: 10.1002/jso.22127. doi:10.1002/jso.22127 |
| [41] | Zhu L, Jiang Y, Wang J, et al. An investigationof125I seed permanent implantation for recurrent carcinoma in the head and neck after surgery and external beam radiotherapy[J]. World J Surg Oncol, 2013, 11:60. DOI: 10.1186/1477-7819-11-60. doi:10.1186/1477-7819-11-60 |
| [42] | Zhu HD, Guo JH, Mao AW, et al. Conventional stents versus stents loaded with (125)iodine seeds for the treatment of unresectable oesophageal cancer: a multicentre, randomized phase 3 trial[J]. Lancet Oncol, 2014, 15(6):612-619. DOI: 10.1016/S1470-2045(14)70131-7. doi:10.1016/S1470-2045(14)70131-7 |
| [43] | Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group[J]. JAMA, 1999, 281(17):1623-1627. DOI: 10.1001/jama.281.17.1623. doi:10.1001/jama.281.17.1623 |
| [44] | Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicenter, diagnostic cohort study[J]. Lancet Oncol, 2018, 19(7):965-974. DOI: 10.1016/S1470-2045(18)30201-8. doi:S1470-2045(18)30201-8pmid:29861116 |
| [45] | Noordman BJ, Wijnhoven BPL, Lagarde SM, et al. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oeso-phageal cancer: a stepped-wedge cluster randomised trial[J]. BMC Cancer, 2018, 18(1):142. DOI: 10.1186/s12885-018-4034-1. doi:10.1186/s12885-018-4034-1pmid:29409469 |
| [46] | Wainberg ZA, Lin LS, DiCarlo B, et al. Phase Ⅱ trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction[J]. Br J Cancer, 2011, 105(6):760-765. DOI: 10.1038/bjc.2011.280. doi:10.1038/bjc.2011.280 |
| [47] | Doi T, Piha-Paul SA, Jalal S, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma[J]. J Clin Oncol, 2018, 36(1):61-67. DOI: 10.1200/JCO.2017.74.9846. doi:10.1200/JCO.2017.74.9846 |
| [48] | Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial[J]. Lancet Oncol, 2017, 18(5):631-639. DOI: 10.1016/S1470-2045(17)30181-X. doi:10.1016/S1470-2045(17)30181-X |
| [49] | Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma[J]. Clin Cancer Res, 2018, 24(6):1296-1304. DOI: 10.1158/1078-0432.CCR-17-2439. doi:10.1158/1078-0432.CCR-17-2439pmid:29358502 |
| [50] | Janjigian YY, Bendell J, Calvo E, et al. Checkmate-032 study: efficacy and safety of nivolumab and nivolmab plus ipilimumab in patients with metastatic esophagogastric cancer[J]. J Clin Oncol, 2018, 36(28):2836-2844. DOI: 10.1200/JCO.2017.76.6212. doi:10.1200/JCO.2017.76.6212pmid:30110194 |
| [51] | Alsina M, Moehler M, Lorenzen S. Immunotherapy of esophageal cancer: current status, many trials and innovative strategies[J]. Oncol Res Treat, 2018, 41(5):266-271. DOI: 10.1159/000488120. doi:10.1159/000488120pmid:29705786 |
| [52] | Meindl-Beinker NM, Betge J, Gutting T, et al. A multicenter open-label phase Ⅱ trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)[J]. BMC Cancer, 2019, 19(1):231. DOI: 10.1186/s12885-019-5446-2. doi:10.1186/s12885-019-5446-2pmid:30871493 |
| [53] | Ralph C, Elkord E, Burt DJ, et al. Modulation of lymphocyte regulation for cancer therapy: a phase Ⅱ trial of tremelimumab in advanced gastric and esophageal adenocarcinoma[J]. Clin Cancer Res, 2010, 16(5):1662-1672. DOI: 10.1158/1078-0432.CCR-09-2870. doi:10.1158/1078-0432.CCR-09-2870 |
| [54] | FDA Approves New Monotherapy Indication for Merck's KEYTRUDA?(pembrolizumab)[EB/OL]. [2019-07-31]. https://www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-new-monotherapy-indication-mercks-keytruda-pembrolizumab/. |
| [55] | Wang H, Mu X, He H, et al. Cancer radiosensitizers[J]. Trends Pharmacol Sci, 2018, 39(1):24-48. DOI: 10.1016/j.tips.2017.11.003. doi:S0165-6147(17)30220-1pmid:29224916 |
| [56] | 康梅, 权循凤. 食管癌放疗增敏剂的临床研究[J]. 国际肿瘤学杂志, 2015, 42(12):932-935. DOI: 10.3760/cma.j.issn.1673-422X.2015.12.013. doi:10.3760/cma.j.issn.1673-422X.2015.12.013 |
| [57] | 邓家营, 王春雨, 赵快乐. 紫杉醇(PTX)在食管癌同期放化疗中的研究进展[J]. 复旦学报(医学版), 2014, 41(5):697-700, 705. DOI: 10.3969/j.issn.1672-8467.2014.05.023. doi:10.3969/j.issn.1672-8467.2014.05.023 |
| [58] | Ruhstaller T, Pless M, Dietrich D, et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase ⅠB/Ⅱ trial (SAKK 75/06)[J]. J Clin Oncol, 2011, 29(6):626-631. DOI: 10.1200/JCO.2010.31.9715. doi:10.1200/JCO.2010.31.9715pmid:21205757 |
| [59] | Li W, Chen P, Zhang N, et al. Endostatin and oxaliplatin-based chemoradiotherapy for inoperable esophageal squamous cell carcinoma: results of a phase Ⅱ study[J]. Oncologist, 2019, 24(4):461-e136. DOI: 10.1634/theoncologist.2019-0119. doi:10.1634/theoncologist.2019-0119 |
| [60] | Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(11):1224-1235. DOI: 10.1016/S1470-2045(14)70420-6. doi:10.1016/S1470-2045(14)70420-6 |
| [61] | 秦尚彬, 王雅棣, 杨俊泉, 等. 甘氨双唑钠胸段食管鳞癌放射增敏作用——Ⅲ期多中心随机对照研究[J]. 中华放射肿瘤学杂志, 2012, 21(5):426-429. DOI: 10.3760/cma.j.issn.1004-4221.2012.05.009. doi:10.3760/cma.j.issn.1004-4221.2012.05.009 |
| [62] | Steward WP, Middleton M, Benghiat A, et al. The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase Ⅰ study[J]. Ann Oncol, 2007, 18(6):1098-1103. DOI: 10.1093/annonc/mdm120. doi:10.1093/annonc/mdm120pmid:17442658 |
| [63] | 龚林吉, 谢佳妮, 朱双, 等. 多功能纳米材料在肿瘤放疗增敏中的应用[J]. 物理化学学报, 2018, 34(2):140-167. DOI: 10.3866/PKU.WHXB201707174. doi:10.3866/PKU.WHXB201707174 |
| [64] | 吕家华, 李涛. 食管癌放疗患者的营养治疗[J]. 肿瘤代谢与营养电子杂志, 2017, 4(2):144-148. DOI: 10.16689/j.cnki.cn11-9349/r.2017.02.003. doi:10.16689/j.cnki.cn11-9349/r.2017.02.003 |
| [65] | Lyu J, Li T, Xie CH, et al. Enteral nutrition in esophageal cancer patients treated with radiotherapy: a Chinese expert consensus 2018[J]. Future Oncol, 2019, 15(5):517-531. DOI: 10.2217/fon-2018-0697. doi:10.2217/fon-2018-0697 |
| [66] | Xu YJ, Cheng JC, Lee JM, et al. A walk-and-eat intervention improves outcomes for patients with esophageal cancer undergoing neoadjuvant chemoradiotherapy[J]. Oncologist, 2015, 20(10):1216-1222. DOI: 10.1634/theoncologist.2015-0178. doi:10.1634/theoncologist.2015-0178 |
| [67] | 吕家华, 李涛, 朱广迎, 等. 肠内营养对食管癌同步放化疗患者营养状况、不良反应和近期疗效影响——前瞻性、多中心、随机对照临床研究(NCT02399306)[J]. 中华放射肿瘤学杂志, 2018, 27(1):44-48. DOI: 10.3760/cma.j.issn.1004-4221.2018.01.009. doi:10.3760/cma.j.issn.1004-4221.2018.01.009 |
| [68] | Fietkau R, Lewitzki V, Kuhnt T, et al. A disease-specific enteral nutrition formula improves nutritional status and functional perfor-mance in patients with head and neck and esophageal cancer under-going chemoradiotherapy: results of a randomized, controlled, multicenter trial[J]. Cancer, 2013, 119(18):3343-3353. DOI: 10.1002/cncr.28197. doi:10.1002/cncr.28197pmid:23765693 |
| [69] | Checkmate-649, a phase 3 trial evaluating opdivo (nivolumab) plus chemotherapy vs. chemotherapy, meets primary endpoints demonstrating superior overall survival and progression-free survival in first-line treatment of gastric and esophageal cancers[EB/OL]. [2020-08-11]. https://news.bms.com/press-release/corporatefinancial-news/checkmate-649-phase-3-trial-evaluating-opdivo-nivolumab-plus-c. |
| [70] | Merck's KEYTRUDA®(pembrolizumab) in combination with chemotherapy significantly improved overall survival and progression-free survival compared with chemotherapy in locally advanced or first-line metastatic esophageal cancer[EB/OL]. [2020-08-19]. https://www.merck.com/news/mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-significantly-improved-overall-survival-and-progression-free-survival-compared-with-chemotherapy-in-locally-advanced-or/. |
| [71] | Opdivo (nivolumab) demonstrated superior disease-free survival in patients with resected esophageal or gastroesophageal junction cancer compared to placebo in the adjuvant setting[EB/OL]. [2020-9-21]. https://news.bms.com/news/details/2020/Opdivo-nivolumab-Demonstrated-Superior-Disease-Free-Survival-in-Patients-with-Resected-Esophageal-or-Gastroesophageal-Junction-Cancer-Compared-to-Placebo-in-the-Adjuvant-Setting/default.aspx. |
| [72] | Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018, 36(27):2796-2803. DOI: 10.1200/JCO.2018.79.1483. doi:10.1200/JCO.2018.79.1483 |
| [73] | Qian D, Wang Y, Zhao G, et al. Tumor remission and tumor-infiltrating lymphocytes during chemoradiation therapy: predictive and prognostic markers in locally advanced esophageal squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2019, 105(2):319-328. DOI: 10.1016/j.ijrobp.2019.06.079. doi:10.1016/j.ijrobp.2019.06.079 |
| [74] | Jayaprakasam VS, Yeh R, Ku GY, et al. Role of imaging in esophageal cancer management in 2020: update for radiologists[J]. AJR Am J Roentgenol, 2020, 215(5):1072-1084. DOI: 10.2214/AJR.20.22791. doi:10.2214/AJR.20.22791 |
| [75] | Ono T. Review of clinical results of charged-particle therapy for esophageal cancer[J]. Esophagus, 2021, 18(1):33-40. DOI: 10.1007/s10388-020-00759-0. doi:10.1007/s10388-020-00759-0 |
| [76] | Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant aivolumab in resected esophageal or gastroesophageal junction cancer[J]. N Engl J Med, 2021, 384(13):1191-1203. DOI: 10.1056/NEJMoa2032125. doi:10.1056/NEJMoa2032125 |
| [77] | Sun H, Yang W, Luo J, et al. Safety and tolerability of neoadjuvant radiotherapy combined with anti-PD-1 antibody toripalimab for locally advanced, resectable esophageal squamous cell cancer: a prospective phase ⅠB trial[J]. Int J Radiat Oncol Biol Phys, 2021, 111(Suppl_3):S102-S103. DOI: 10.1016/j.ijrobp.2021.07.238. doi:10.1016/j.ijrobp.2021.07.238 |
| [78] | Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294):27-40. DOI: 10.1016/S0140-6736(21)00797-2. doi:10.1016/S0140-6736(21)00797-2pmid:34102137 |
| [79] | Chau I, Dok Y, Ajani JA, et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study[J]. J Clin Oncol, 2021, 39(18_suppl): LBA4001-LBA4001. DOI: 10.1200/JCO.2021.39.15_suppl.LBA4001. doi:10.1200/JCO.2021.39.15_suppl.LBA4001 |
| [80] | Boku N, Ryu MH, Kato K, et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase Ⅱ trial (ATTRACTION-4)[J]. Ann Oncol, 2019, 30(2):250-258. DOI: 10.1093/annonc/mdy540. doi:S0923-7534(19)31036-1pmid:31987422 |
| [81] | Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemothe-rapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study[J]. Lancet, 2021, 398(10302):759-771. DOI: 10.1016/S0140-6736(21)01234-4. doi:10.1016/S0140-6736(21)01234-4 |
| [82] | Kojima T, Shah MA, Muro K, et al. Randomized phase Ⅲ KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer[J]. J Clin Oncol, 2020, 38(35):4138-4148. DOI: 10.1200/JCO.20.01888. doi:10.1200/JCO.20.01888 |
| [83] | Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial[J]. JAMA, 2021, 326(10):916-925. DOI: 10.1001/jama.2021.12836. doi:10.1001/jama.2021.12836 |
| [84] | Peng Z, Liu T, Wei J, et al. A phase Ⅱ study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers[J]. J Clin Oncol, 2020, 38(15 suppl):4560. DOI: 10.1200/JCO.2020.38.15_suppl.4560. doi:10.1200/JCO.2020.38.15_suppl.4560 |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
